Cargando…

Tocilizumab in critically ill COVID-19 patients: An observational study

Tocilizumab decreases inflammatory response in the cytokine storm which is one of the mechanisms behind the development of ARDS in COVID-19 patients. The objective of our study was to determine response of tocilizumab in patients suffering from COVID-19 by analyzing clinical parameters and inflammat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mushtaq, Muhammad Z., Mahmood, Saad B.Z., Almas, Aysha, Ather Wasti, Syed, Ahsan Ali, Syed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604692/ https://www.ncbi.nlm.nih.gov/pubmed/34838490 http://dx.doi.org/10.1016/j.intimp.2021.108384

Ejemplares similares

Outcome of COVID-19 patients with use of Tocilizumab: A single center experience
por: Zain Mushtaq, Muhammad, et al.
Publicado: (2020)

Cognitive Impairment in Type 2 Diabetes Mellitus: An Observational Study from Lower Middle-Income Country
por: Mahmood, Saad B. Z., et al.
Publicado: (2022)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Lower limb axonal mononeuropathies as sequelae of COVID-19: a case report and review of literature
por: Mahmood, Saad Bin Zafar, et al.
Publicado: (2022)

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
por: Huang, Edmund, et al.
Publicado: (2021)

Acuity level of care as a predictor of case fatality and prolonged hospital stay in patients with COVID-19: a hospital-based observational follow-up study from Pakistan
por: Almas, Aysha, et al.
Publicado: (2021)

Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
por: Bhandari, Sudhir, et al.
Publicado: (2021)

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
por: Elhazmi, Alyaa, et al.
Publicado: (2023)

Invasive pulmonary aspergillosis in critically ill patients with pneumonia due to COVID-19, influenza, and community-acquired pneumonia: A prospective observational study
por: Ali, Syed Ahsan, et al.
Publicado: (2022)

The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19
por: Zacharias, Harry, et al.
Publicado: (2022)

Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?
por: Camou, Fabrice, et al.
Publicado: (2022)

Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
por: Szabo, Robert, et al.
Publicado: (2023)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
por: Hafez, Wael, et al.
Publicado: (2022)

Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a Façade for prognostic markers
por: Atallah, Bassam, et al.
Publicado: (2020)

Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in “non-critically-ill” patients on hemodialysis
por: Castellano, Giuseppe, et al.
Publicado: (2020)

The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study
por: Korayem, Ghazwa B., et al.
Publicado: (2022)

A retrospective review of antiphospholipid syndrome from a South Asian country
por: Mushtaq, Muhammad Zain, et al.
Publicado: (2021)

Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study
por: Burger, Barrett J., et al.
Publicado: (2023)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
por: Zhao, Jie, et al.
Publicado: (2020)

The evolution of clot strength in critically ill COVID-19 patients: a prospective observational thromboelastography study
por: Muzaffar, Syed Nabeel, et al.
Publicado: (2022)

AORTIC VALVE ENDOCARDITIS AS A COMPLICATION OF TOCILIZUMAB TREATMENT IN COVID 19 PATIENT
por: Ashraf, Shoaib, et al.
Publicado: (2021)

Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients
por: Cala-García, Juan David, et al.
Publicado: (2020)

Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
por: Mady, Ahmed, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases
por: ElSeirafi, Mohamed M, et al.
Publicado: (2020)

What's New in Critical Illness and Injury Science? Mortality effects of tocilizumab for patients admitted with COVID-19 pneumonia
por: Miller, Andrew C., et al.
Publicado: (2021)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

COVID-19 INDUCED CARDIOMYOPATHY SUCCESSFULLY TREATED WITH TOCILIZUMAB
por: Fakhra, Sadaf, et al.
Publicado: (2022)

COVID-19 Induced Cardiomyopathy Successfully Treated with Tocilizumab
por: Schreiber, Ariyon, et al.
Publicado: (2022)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab
por: Rashad, Alaa, et al.
Publicado: (2021)

Association of Tocilizumab and Invasive Aspergillosis in Critically Ill Patients with Severe COVID-19 Pneumonia and Acute Respiratory Distress Syndrome
por: Wu, Kuo-Lun, et al.
Publicado: (2022)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
por: Dufranc, Etienne, et al.
Publicado: (2020)

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
por: Ip, Andrew, et al.
Publicado: (2020)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
por: Zeng, Jia, et al.
Publicado: (2020)

Consistency of recommendations from clinical practice guidelines for the management of critically ill COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2021)

Exploring the relationship between SARS‐CoV‐2 variants, illness severity at presentation, in‐hospital mortality and COVID‐19 vaccination in a low middle‐income country: A retrospective cross‐sectional study
por: Mushtaq, Muhammad Zain, et al.
Publicado: (2023)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oi6ngfogu4mp6jo2d5jvko2ab6